It has been proven that PD-1/PD-L1 inhibitors benefit cervical cancer treatment by markedly reinvigorating the anti-tumor immune response of T cells (Wang et al., 2019; Balanca et al., 2020; Lyu et al., 2020). The gene discussed is CD274; the disease is cervical cancer.